Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Galmed Pharmaceuticals Ltd

Healthcare US GLMD

0.5801USD
0.0001(0.02%)

Last update at 2026-06-22T15:03:00Z

Day Range

0.530.61
LowHigh

52 Week Range

0.412.68
LowHigh

Fundamentals

  • Previous Close 0.58
  • Market Cap4.80M
  • Volume603123
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.42700M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.39

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.30900M -7.51700M -6.91200M -17.86600M -32.46700M
Minority interest - - - - -
Net income -10.30900M -7.51700M -6.91200M -18.57100M -31.94800M
Selling general administrative 3.64M 3.26M 3.72M 4.66M 5.66M
Selling and marketing expenses - 0.04M 3.89M - -
Gross profit - -0.08300M -0.03100M -0.03500M -0.04200M
Reconciled depreciation 0.00000M 0.08M 0.03M 0.04M 0.04M
Ebit - -6.27800M -7.49200M -17.65100M -32.88100M
Ebitda -8.51000M -6.19500M -7.46100M -17.12600M -32.83900M
Depreciation and amortization - 0.08M 0.03M 0.53M 0.04M
Non operating income net other - - - - -
Operating income -8.51000M -6.27800M -7.49200M -17.65100M -32.88100M
Other operating expenses 8.51M 6.28M 7.49M 17.65M 32.88M
Interest expense - 0.01M 0.01M 0.21M 0.04M
Tax provision - - - - -
Interest income 0.91M 0.50M 0.38M 0.30M 0.56M
Net interest income 0.82M -0.12200M 0.74M 0.28M 0.52M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 0.70M -0.51900M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 8.51M 6.20M 7.46M 17.65M 32.88M
Cost of revenue - 0.08M 0.03M 0.04M 0.04M
Total other income expense net -1.79900M -1.23900M 0.58M -0.21500M 0.41M
Discontinued operations - - - - -
Net income from continuing ops -10.30900M -7.51700M -7.53500M -17.86600M -32.46700M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 18.63M 18.50M 16.63M 16.56M 36.60M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.39M 0.58M 0.32M - 1.16M
Total liab 2.85M 2.17M 2.75M 3.14M 6.11M
Total stockholder equity 15.78M 16.33M 13.88M 13.42M 30.50M
Deferred long term liab - - - - -
Other current liab 0.84M 0.86M 0.83M 0.53M 1.01M
Common stock 3.41M 0.74M 0.21M 0.07M 0.07M
Capital stock 3.41M 0.74M 0.21M 0.07M 0.07M
Retained earnings -210.77800M -200.46900M -192.95200M -186.04000M -168.17400M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 3.98M 4.65M 2.98M 2.02M 2.88M
Cash and equivalents - - - - -
Total current liabilities 2.85M 2.17M 2.75M 3.09M 5.88M
Current deferred revenue - - - - -
Net debt -3.98500M -4.65200M -2.93700M -1.97200M -2.65500M
Short term debt - - 0.04M - -
Short long term debt - - - - -
Short long term debt total - - 0.04M 0.04M 0.23M
Other stockholder equity 223.46M 216.47M 207.08M 200.14M 198.77M
Property plant equipment - - - 0.34M -
Total current assets 18.63M 16.12M 13.24M 14.72M 36.05M
Long term investments 0.00000M 2.12M 3.27M 1.50M -
Net tangible assets - - - - -
Short term investments 14.17M 10.68M 9.78M 11.77M 31.93M
Net receivables 0.08M 0.21M 0.17M 0.12M 1.12M
Long term debt - - - - -
Inventory - - - - -1.04600M
Accounts payable 2.00M 1.31M 1.88M 2.56M 4.87M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.30300M -0.41600M -0.45400M -0.74500M -0.17100M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.26M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 2.38M 3.39M 1.84M 0.55M
Capital lease obligations - 0.00000M 0.04M 0.04M 0.23M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -3.37500M -1.11100M 0.50M 17.56M 11.46M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities -3.37500M -1.11100M - - -
Net borrowings - - - - -
Total cash from financing activities 9.03M 8.79M 6.18M 0.07M 17.37M
Change to operating activities - - - - -
Net income -10.30900M -7.51700M -6.91200M -17.86600M -32.46700M
Change in cash -0.66400M 1.79M 0.85M -0.86800M -4.06200M
Begin period cash flow 4.77M 2.98M 2.13M 3.00M 7.06M
End period cash flow 4.11M 4.77M 2.98M 2.13M 3.00M
Total cash from operating activities -6.31500M -5.88000M -6.13700M -18.50100M -32.89200M
Issuance of capital stock 9.03M 8.79M 6.18M 0.07M 17.37M
Depreciation 0.00000M 0.08M 0.03M 0.04M 0.04M
Other cashflows from investing activities - -0.25000M - - -
Dividends paid - - - - -
Change to inventory - - - -0.30000M 0.31M
Change to account receivables 0.24M -0.19200M 0.34M 0.30M -0.31300M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - 0.00619M 0.00007M 0.02M
Change to netincome - - - 1.78M 1.78M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00400M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.91M -0.72800M 0.13M -2.45100M -2.45000M
Stock based compensation 0.55M 0.53M 0.89M 1.30M 1.89M
Other non cash items 2.54M 1.75M 1.01M 0.48M 0.01M
Free cash flow -6.31500M -5.88000M -6.13700M -18.50500M -32.90300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GLMD
Galmed Pharmaceuticals Ltd		 0.0001 0.02% 0.58 - - 61.38 0.32 6.09 0.32
NVO
Novo Nordisk A/S		 2.50 5.78% 45.69 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.55 1.23% 457.18 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.77 1.60% 600.17 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Galmed Pharmaceuticals Ltd

16 Abba Hillel Road, Ramat Gan, Israel, 5250608

Key Executives

Name Title Year Born
Mr. Allen Baharaff Co-Founder, Pres, CEO & Chairman 1965
Mr. Guy Nehemya COO & Data Protection Officer 1985
Mr. Yohai Stenzler CPA Chief Accounting Officer 1983
Dr. Liat Hayardeny Chief Scientific Officer 1967
Mr. Doron Cohen Chief Financial Officer 1967
Ms. Yael Hollander VP of Legal Affairs & Strategy 1983
Ms. Shani Ganon HR Mang. NA
Dr. Tali Gorfine Medical Consultant 1970
Mr. Niv Alon Head of PMO NA
Mr. Allen Baharaff Co-Founder, President, CEO & Chairman 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions